What You Should Know:
– GoodRx, a prominent prescription savings platform in the U.S., has joined forces with ARS Pharmaceuticals to offer the lowest discounted cash price for neffy®, a revolutionary needle-free treatment for Type I allergic reactions.
– The partnership makes neffy available for $199 at over 70,000 pharmacies across the nation, exclusively through GoodRx.
neffy: A Needle-Free Solution for Anaphylaxis
Allergies and allergic reactions affect over 100 million Americans annually, with anaphylaxis posing a serious threat. Approved by the FDA in August, neffy is the first needle-free treatment for anaphylaxis and other Type I allergic reactions, offering an alternative to traditional auto-injectors. By delivering epinephrine nasally, neffy eliminates the need for needle injections, a major hurdle for many, especially children and adults who require epinephrine.
GoodRx: Championing Innovation and Accessibility
GoodRx is dedicated to making essential medications more accessible and affordable while promoting innovation in healthcare. The company’s partnership with ARS Pharmaceuticals highlights this commitment, ensuring that neffy is available at a lower price, breaking down barriers to anaphylaxis treatment and offering a more convenient option for millions of Americans.
“We’re thrilled about neffy’s U.S. Food and Drug Administration approval, so people with severe allergies don’t have to endure needle-injection of epinephrine, which can be fraught with anxiety and fear, and can carry a device that’s small and effective. Through our partnership with GoodRx, we can offer our innovation in retail pharmacies along with patient programs to support its affordability,” said Richard Lowenthal, Co-Founder, President, and Chief Executive Officer of ARS Pharmaceuticals. “We’re grateful that GoodRx’s platform has helped us reach more patients and caregivers to access a needle-free option so they can respond swiftly during a Type 1 allergic reaction.”
Consumers can access the savings on neffy at www.goodrx.com/neffy
